Navigation Links
Access to existing medical treatments could save more lives than spending to improve the treatments

More lives could be saved in the United States by spending less money on making medical treatments better and more on getting existing treatments to the patients who need them, according to a study published by a Virginia Commonwealth University family medicine and public health physician.

"For every dollar Congress gives the National Institutes of Health to develop blockbuster treatments, it spends only one penny to ensure that Americans actually receive them," said Steven H. Woolf, M.D., professor and director of research in VCU's Department of Family Medicine and a member of the National Academy of Sciences' Institute of Medicine. "This reflects, in part, a misperception that the improved drugs, procedures and the like will improve health outcomes, and that does happen. But the health improvement would be far greater if we worried less about making incremental improvements on existing treatments and more on the system barriers that impede Americans from receiving those treatments correctly." The study was coauthored by Robert E. Johnson, Ph.D., an associate professor in VCU's Department of Biostatistics.

Woolf and Johnson, whose study appears in the Dec. 6 issue of the Annals of Family Medicine, said a mathematical construct proves the point. They used two case studies -- one involving statins and the other antiplatelet drugs -- to show that the billions of dollars spent on new generation drugs saved fewer lives and prevented fewer strokes than if the existing drugs had been taken by all patients who could benefit. They cited reports that Americans receive only half of recommended health care services and that disparities in care are worse for minorities and disenfranchised patients.

The study poses a contrast between efficacy, or how well a treatment works, and what they call the "fidelity of health care." Independent of the efficacy, fidelity is the extent to which the health care system provides patients the precise interventions they ne ed, delivered properly, precisely when they need them.

Woolf illustrated the concept with an example of a theoretical disease that claims 100,000 lives a year. If a drug is available that reduces the mortality rate from that disease by 20 percent, it has the potential to save 20,000 lives each year. But if only 60 percent of eligible patients receive the drug, only 12,000 deaths will be averted. Closing the gap in care -- making it available to 100 percent of eligible patients -- would save 8,000 additional lives. To save 8,000 additional lives by making a better drug and without closing the gap in care -- delivering the better drug to only 60 percent of eligible patients -- the drug's lowering of mortality would have to be increased from 20 percent to 33 percent. Woolf calls this the "break-even point" and notes that it is an unrealistic goal for many treatments. The study shows that the billions invested in statins and clot-busting drugs failed to reach the break-even point, thus saving fewer lives than if gaps in care had been rectified.

For example, getting aspirin to all eligible patients would have prevented more strokes than were prevented by developing more potent and more expensive antiplatelet drugs, Woolf said. In another example, Woolf and Johnson estimate that for every heart attack death prevented by the development of the new statin, Crestor, seven deaths would have been prevented by sticking with older, less potent statins but adopting simple reminder systems such as post-it notes on the front of charts that would alert clinicians when patients need cholesterol-lowering therapy.

"Society's huge investment in technological innovations that only modestly improve efficacy, by consuming resources needed for improved delivery of care, may cost more lives than it saves," they wrote. "The misalignment of priorities is driven partly by the commercial interests of industry and by the public's appetite for technological breakthrou ghs, but health outcomes ultimately suffer." The authors discuss the relevance of this concept at a time when the nation is struggling with the escalating costs of health care and unsatisfactory performance on quality.

"Health, economic and moral arguments make the case for spending less on technological advances and more on improving systems for delivering care," he said.


'"/>

Source:Virginia Commonwealth University


Related biology news :

1. Open Access journals get impressive impact factors
2. Access to antiretrovirals unlikely to reduce HIV infection rates
3. Gadonanotubes greatly outperform existing MRI contrast agents
4. Automatic extraction of gene/protein biological functions from biomedical text
5. Vital step in cellular migration described by UCSD medical researchers
6. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
7. UCSD medical/bioengineering reseachers show titanium debris satobtage artificial joints
8. Innovative coating could give medical implants a longer life
9. Natural tumor suppressor in body discovered by UCSD medical researchers
10. Protein synthesis can be controlled by light, opening way for new scientific, medical applications
11. Modified collagen could yield important medical applications
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/15/2016)... , March 15, 2016 Yissum Research ... the technology-transfer company of the Hebrew University, announced today ... remote sensing technology of various human biological indicators. Neteera ... $2.0 million from private investors. ... on the detection of electromagnetic emissions from sweat ducts, ...
(Date:3/14/2016)... 2016 http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ... --> DERMALOG, le leader de ... lecteurs d,empreintes digitales pour l,enregistrement des réfugiés en ... pour produire des cartes d,identité aux réfugiés. DERMALOG ...
(Date:3/11/2016)... India , March 11, 2016 ... a new market research report "Image Recognition Market by ... Application (Marketing and Advertising), by Deployment Type (On-Premises and ... Forecast To 2022", published by MarketsandMarkets, the global market ... 2015 to USD 29.98 Billion by 2020, at a ...
Breaking Biology News(10 mins):
(Date:5/27/2016)... ... 27, 2016 , ... Doctors in Italy, Japan, the UK and the US ... protein (BAP1) gene and its link to malignant mesothelioma. Surviving Mesothelioma has just posted ... full article now. , The studies analyzed for the new report included more ...
(Date:5/26/2016)... YORK , May 26, 2016 ... today that it will be a featured presenter at the ... in New York City at the ... Denis Corin , Q BioMed Inc. CEO, is scheduled to ... will cover the company,s business strategy, recent developments and outline ...
(Date:5/25/2016)... ... 2016 , ... Lajollacooks4u has become a rising hotspot for specialized team building ... top attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm and Elsevier, have ... experience. , Each event kicks off with an olive oil and salt-tasting competition. ...
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens ... for mesothelioma may be hampering the research that could lead to one good one. ... to read it now. , The team evaluated 98 mesothelioma patients ...
Breaking Biology Technology: